6 recruiting, 5 active not recruiting. 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Recruiting 6, Active not recruiting 5 |
Follow Volrustomig: new trials by email Literature Review of Volrustomig trials Research Report on Volrustomig
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer Volrustomig, Carboplatin, Paclitaxel - Head and Neck Cancer, HPV | Phase 2 | Recruiting | University of Chicago | 38 | 2025-10-07 | 2026-03-04 |
| A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA) Volrustomig - Locally Advanced Cervical Cancer | Phase 2 | Active not recruiting | AstraZeneca | 37 | 2025-03-31 | 2026-08-18 |
| A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer Volrustomig, FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan), Bevacizumab - Metastatic Colorectal Cancer | Phase 2 | Active not recruiting | AstraZeneca | 82 | 2025-03-12 | 2026-10-22 |
| Volrustomig Priming Regimens Exploratory Phase II Platform Study Volrustomig, Carboplatin, Pemetrexed - Non-small Cell Lung Cancer | Phase 2 | Active not recruiting | AstraZeneca | 194 | 2024-08-27 | 2026-09-29 |
| Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors Volrustomig, Cisplatin, Carboplatin - Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy) | Phase 2 | Recruiting | AstraZeneca | 257 | 2024-08-22 | 2026-09-11 |
| Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer Volrustomig, Bevacizumab, Lenvatinib - Hepatocellular Carcinoma, Biliary Tract Cancer | Phase 2 | Active not recruiting | AstraZeneca | 294 | 2023-04-24 | 2026-08-24 |
| Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Rilvegostomig, Volrustomig, FOLFOX - Gastric Cancer | Phase 2 | Recruiting | AstraZeneca | 163 | 2023-01-16 | 2026-05-14 |
| Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil - Endometrial Cancer, Gastric Cancer | Phase 2 | Recruiting | AstraZeneca | 454 | 2022-09-06 | 2026-09-23 |
| Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer Durvalumab, Oleclumab, Monalizumab - Non-small Cell Lung Cancer | Phase 2 | Recruiting | AstraZeneca | 630 | 2022-04-14 | 2026-10-21 |
| WIRE - Novel Treatments in Renal Cell Cancer Olaparib, Cediranib, Volrustomig - Renal Cell Cancer | Phase 2 | Recruiting | CCTU- Cancer Theme | 134 | 2020-07-27 | 2026-09-25 |
| Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) Fluorouracil (5-FU), Capecitabine, Durvalumab - Gastric Cancer | Phase 2 | Active not recruiting | AstraZeneca | 452 | 2020-06-03 | 2026-08-28 |
Stomach Neoplasms (3) · Biliary Tract Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Adenocarcinoma (1) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Head and Neck Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1)
AstraZeneca (9) · CCTU- Cancer Theme (1) · University of Chicago (1)
United States (9) · South Korea (8) · Taiwan (8) · China (7) · Italy (7) · Spain (7) · United Kingdom (7) · Canada (5) · Japan (5) · France (4) · Germany (4) · Australia (2) · Brazil (2) · Netherlands (2) · Poland (2)
Brent O'Carrigan (1) · Grant D Stewart (1) · Tina Cascone, MD (1)
PMID 34794412, PMID 38981998, PMID 40341124, PMID 40450142, PMID 41369900
2023 (3), 2019 (1)